Inkforgelaunchhandbook.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Inkforgelaunchhandbook.Pdf Early Career Researchers.. In hosting this event we would like to say thank you to our industrial partners, who have helped us to shape this program so far. You have done this with dispassionate honesty and enthusiasm, which has been most welcome and encouraging to us all. It has been a steep learning curve for us and we know this is only the beginning. Be reassured that we appreciate the time you are giving and we value hearing your advice and your requests. We may not always get it right but we are genuinely committed to nurturing this partner- ship in a mutually beneficial way that will create a ‟culture of interaction with industry‟ in our institution. Our aim is that the next generation of research leaders will be able to thrive through collaboration, and will be a testament to those who dedicated time to their training. To the academic staff and early career researchers, we would like to encourage you to take up this unique opportunity to increase your network of industrial partners, let them know your strengths and discover their needs. We are entering a new era in the history of universities and the opportunity to network with industrial partners will enable us to en- hance the impact of our research. To those in management positions, we invite you to en- gage with our help in building the InKForge portfolio of events within departments . We hope you will ensure that the early career researchers working with you take part in this process and have the opportunity to learn how it is done. Be reassured that the Early Ca- reer Group, particularly Dr Kay Guccione will be there to support you in making this hap- pen. Finally I would like to say my personal thank you to Dr Kay Guccione, who was able to see the potential of what we were trying to achieve from the start and has been working with great passion and dedication to transform few ideas in a concrete program of work. My thanks go also to Lesley Keers, InKForge administrator, who has supported us in the or- ganization of this event with great enthusiasm. I hope you enjoy the evening and this will be the first of many InKForge events to come. Ilaria Bellantuono Chair of the Early Career Group Early Career Researchers.. Dr Dan Hampshire Research Associate Cardiovascular Science Dan has worked in the field of molecular genetics for approximately eleven years, specifically on its appli- cation to research into single gene disorders. His initial research focused on neuro-development disor- ders, specifically the use of molecular genetic techniques to identify and characterise genes involved in neuro-development. During this period he also undertook an industrial placement with GlaxoSmithKline as part of an MRC Industrial CASE studentship. Post-PhD Dan‟s research has focused on the inherited bleeding disorder von Willebrand disease. Specifically, his research concerns the identification of further mechanisms involved in the pathogenesis of this disorder. However, he has also developed an active inter- est into the wide natural variation of von Willebrand factor (VWF) levels in plasma and the mechanisms which could influence plasma VWF levels, including the transcriptional / miRNA regulation of the VWF gene and other genetic loci acting as modifiers. Dr Ed Guccione Research Associate Infection & Immunity Ed is a molecular microbiologist who has worked in a number of areas of the course of a 10-year career. Ed‟s PhD was an Industrial CASE studentship with Don Whitley Scientific Ltd that focused on the funda- mental metabolism available to foodborne pathogen Campylobacter jejuni. He continued his work with the pathogen developing novel chemostat culture system for the notoriously fastidious organism, to enable reliable transcriptomic analysis through a range of robustly controlled conditions. Currently, Ed is apply- ing his molecular microbiology skills to developing a new technique for gene expression analysis of Neis- seria spp. during human colonisation. Outside of academia, Ed is a Chief Executive Officer of a local Arts Charity and its trading arm. Dr Caroline Parkin Research Associate Biomedical Science Caroline Parkin uses zebrafish as a model for studying developmental and medical genetics, for much of the last ten years she‟s been at the Centre for Developmental and Biomedical Genetics (CDBG) at the Uni- versity of Sheffield. She can tell you (with some caveats) how the digestive system forms, and the implica- tions for the development of human birth defects and diabetes (her PhD subject); how muscle fibres de- velop, grow and fuse (a post-doc carried out at IMCB in Singapore) and how different drugs that were tested on zebrafish can be used to treat human diseases (a post-doc at CDBG). But she‟s now looking at something new: how stems cells are regulated in the adult brain, with specific emphasis on the hypothala- mus. Zebrafish provide an ideal model for this work as they readily regenerate neural tissue. In addition to her research she spends a lot of time doing outreach work, which ranges from maintaining a website about zebrafish in medical research (www.fishforscience.com) to running day-long molecular biology clas- ses for A-level students to giving a 6 minute and 40 second presentation on her work to the general public at a Pecha Kucha night Dr Michael Trikic Research Associate Oncology Michael works in the Institute for Cancer Studies within the Department of Oncology, The Medical School, University of Sheffield. Michael has 10 years experience of working in university and commercial research laboratories and in 2005 moved to Sheffield to study for a PhD in immunology using zebrafish as a model organism, in the Department of Molecular Biology and Biotechnology. He finished his PhD in a little over 3 years and published a paper based on his findings. He then took up his current position researching the interaction between kinases and small molecule inhibitors, with the aim of developing an understanding of kinase biology in cancers and improving tumour targeting for future therapies. Early Career Researchers Early Career Researchers.. Dr David Finger Research Fellow Chemistry David is currently a Marie Curie International Incoming Fellow (MC-IIF) at the University of Sheffield and a member of the Board of Director (BoD) of the National Postdoctoral Association (NPA). Before becoming an MC-IIF, David was an extramural NIH Ruth Kirschstein Postdoctoral Fellow at the City of Hope (COH) Beckman Research Institute near Los Angeles. David earned his B.A. in biochemistry from Ithaca College. After a three month internship in the Department of Vaccine Serology at Merck, Inc. in West Point, PA, Da- vid moved to Los Angeles to earn his doctorate in Biochemistry and Molecular Biology at University of Cali- fornia, Los Angeles (UCLA) under the direction of Professor Juli Feigon. Before becoming a member of the BoD of the NPA, David previously served as Chair (2009) and Vice Chair (2010) of the Outreach Commit- tee in addition to volunteering (2007-2009) for several other sub-committees of the Meetings Committee. Dr Aneurin Kennerley Research Associate Psychology Aneurin is a Magnetic Resonance Physicist for the fMRI facility in the Department of Psychology. His role includes overseeing the running of MRI based experimental research in the neuro-imaging facilities within the department, and coordinating MRI research carried out in the imaging Unit including that undertaken for internal and external customers. Aneurin obtained his PhD from the University of Sheffield in 2006. In 2010 he was awarded the AstraZeneca Prize for innovative in-vivo MRI research at the British Chapter of the International Society of Magnetic Resonance in Medicine conference. Dr Daniel Kelly Research Associate Human Metabolism Daniel completed an undergraduate degree in combined honours Human Biology and Human Psychology at Aston University in Birmingham. As part of this course he spent a year in industry working for Unilever R&D as a research assistant within a team of biomedical scientists investigating biomarkers of stress and heart health/lifestyle interventions. This placement triggered an interest in biomedical research and he spent almost two years working as a laboratory technician at Sheffield Hallam University. This led him to undertake a PhD at the same University investigating the effects of testosterone on the inflammatory pathogenesis of atherosclerosis. He is currently a postdoctoral research associate at the University of Sheffield focussing on the role of testosterone in cardiovascular disease and comorbidities such as diabe- tes and metabolic syndrome. Dr Simon Palfreyman Research Nurse/Honorary Lecturer ScHARR Simon‟s professional background is as a registered nurse. He currently has a three year post-doctoral NIHR (National Institute for Health Research) clinical lectureship in tissue viability. The post has both a clinical component based within Sheffield Teaching Hospitals NHS Foundation Trust, and a research pro- ject which is within the field of outcome measurement. To undertake his PhD he gained a Smith and Nephew Foundation scholarship to develop a quality of life questionnaire which could be used to examine the effectiveness of treatments for venous ulceration. Simon has successfully applied for and been a co- applicant on a range of research studies within tissue viability and service delivery. He has formed re- search collaborations with Sheffield Hallam University, Sheffield University and Sheffield Teaching Hospi- tals. Simon‟s has experience of undertaking both qualitative and quantitative research. His research inter- ests are concerned with the measurement and valuation of health, particularly in relation to tissue viabil- ity/wound care. Early Career Researchers Early Career Researchers.. Praveen Thokala Research Associate ScHARR Praveen is a health economic modeller at Health Economics and Decision Science (HEDS) in the School of Health and Related Research (ScHARR) at the University of Sheffield.
Recommended publications
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • United States Securities and Exchange Commission Washington, D.C
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1032470 (State or other jurisdiction of (I.R.S. Employer Identification incorporation or organization) No.) Fifth Floor, Waterloo Exchange Waterloo Road, Dublin 4, Ireland 011-353-1-634-7800 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on Title of each class which registered Ordinary shares, nominal The NASDAQ Stock Market value $0.0001 per share LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Consolidation Revisited Is the Founder of Managing Resources, a Date Received *In Revised Form) 8Th October, 2001 Consultancy Focused on the Life Science Industries
    Alan Williams Consolidation revisited is the founder of Managing Resources, a Date received *in revised form) 8th October, 2001 consultancy focused on the life science industries. The Alan Williams company undertakes strategic assignments and also assists public and private sector clients with regulatory affairs, investor Abstract In 1998, the author produced two papers that argued that consolidation was relations and human a necessary activity for biotechnology companies to pay greater attention to. Three resources development. years later a further consideration of the subject seems worthwhile. Examples of Alan has also been an investment manager in successful consolidators are reviewed. a venture capital company, and held Keywords: consolidation, mergers, acquisitions marketing and licensing positions in Fisons. Introduction drink, vaccines and animal health but there is now greater focus on the highest In the early/mid-1970s, the pharmaceutical pro®tability sector, human pharmaceuticals. industry consisted of more than 100 At the time of writing, GSK is rumoured to research-based businesses of some be a possible purchaser of Bayer's signi®cant size, although none of them pharmaceutical business, the future of could convincingly claim a global presence. which has been questioned after the Typically, a leading company had a strong withdrawal of cerivastatin. position in its local market "examples Aventis, the eighth largest pharmaceutical included Merck and P®zer in the USA, company by sales in 2000,1 includes the Bayer in Germany, Beecham in the UK, operations of 1970s companies such as Roussel-Uclaf in France and Fujisawa in Rhone-Poulenc, Rorer, Fisons, Hoechst, Japan) and possibly some other Marion, Richardson Merrell, and some neighbouring countries "US companies in smaller companies.
    [Show full text]
  • Annual Report and Accounts 2015 (PDF)
    Adding precision to medicine Annual report and accounts 2015 Overview and strategic report Proteome Sciences in brief Proteome Sciences in brief Proteome Sciences is a leading protein biomarker company specialising Mission and vision Our strategy in proteomics and peptidomics services and applications, and best-in-class Proteomics explained mass spectrometry protein analysis capability. (inside front cover) We have developed a broad portfolio of novel, high value protein biomarker 01 Adding precision to medicine content addressing numerous disease areas where there is unmet need, The future of healthcare is undoubtedly precision medicine or where the ranges of existing diagnostic or therapeutics available have severe 02 Mapping the future of healthcare limitations. These include neurodegenerative diseases, stroke and cancer with precision and where biomarker product candidates have the potential to transform disease 04 Chairman’s Message management and treatment. 05 Key performance indicators 06 Proteome Sciences at a glance Through our novel biomarker discovery both internally and with collaborative 08 Adding precision to medicine partners, our goal is to improve the quality of life for patients with debilitating The precision measures and life-threatening diseases. for better understanding 10 Faster, more efficient and with precision accuracy Mission and vision 12 Our business model Proteome Sciences is a life sciences company delivering content for precision 13 Our measures for success medicine through its services, biomarkers and reagents. We have a strong 14 Strategic Report track record in discovery and innovation supported by intellectual property. Governance and financial statements We use high sensitivity proprietary technologies to detect biomarkers 22 Senior Management Team (differentially expressed proteins from body fluids or tissue in diseases) and to and Board of Directors make rapid assays for testing.
    [Show full text]
  • Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission
    Shire Pharmaceuticals Group plc Annual review and summary financial statement 2003 Shire: a focused global pharmaceutical company Focusing on a bright future Shire Pharmaceuticals Group plc The Shire mission Our mission is to become the leading company in meeting the needs of the specialist physician. We want to achieve this by developing and Contents 01 Financial highlights marketing products of the highest quality 02 Chairman’s statement 04 Chief Executive Officer’s review for the treatment of serious diseases, 06 Product portfolio 07 Product development pipeline which are treated by medical specialists. 08 Operating review 22 CSR: Corporate and social responsibility 24 Financial review We aim to provide high quality and effective 28 Board of Directors 30 The Executive Committee products that enhance the health and 32 Directors’ remuneration report 44 Corporate governance quality of life of people around the world statement Financial Statements and contribute to the long-term business 48 Statement of Directors’ responsibilities – Report of success of our Company, to the benefit independent auditors 49 Consolidated balance sheets 50 Consolidated statement of all our stakeholders. of operations 51 Consolidated statements of changes in shareholders’ equity We are driven by the needs of all our 52 Consolidated statements of cash flows stakeholders: patients, their families and 53 Notes to the consolidated financial statements 87 Five-year review caregivers, doctors and medical specialists, 88 Summary financial statement 93 Notes to summary employees and partner companies, the financial statement community in which we live and work and, Other 94 Shire head office and main operating locations of course, our shareholders.
    [Show full text]
  • Annual Report 2010 Annual Report 2010 15/03/2011 14:26 Page FC1
    8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page FC1 Shire plc Annual ReportShire and Accounts 2010 Shire plc Annual Report and Accounts 2010 Delivering value Delivering value www.shire.com 8100 Annual Report 2010_Annual Report 2010 15/03/2011 14:26 Page IFC1 Shire plc Annual Repo Shire trademarks The following are trademarks either owned or licensed by Shire plc or companies within the Shire group (the ‘Group’) which are the subject of trademark registrations in certain territories, or which are owned by third-parties as indicated and referred to in this Annual Report: ADDERALL XR® (mixed salts of a single entity amphetamine) ADDERALL® (mixed salts of a single entity amphetamine) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (‘Salix’)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (‘Warner Chilcott’))) ATRIPLA® (trademark of Bristol Myers Squibb Company (‘BMS’) and Gilead Sciences, Inc. (‘Gilead’)) BERINERT P® (trademark of Aventis Behring GmbH) CALCICHEW® range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended-release capsules) CEREZYME® (trademark of Genzyme Corporation (‘Genzyme’)) CINRYZE® (trademark of Viropharma Biologics, Inc.) CLAVERSAL® (trademark of Merckle Recordati) COLAZAL® (trademark of Salix Pharmaceuticals, Inc.) COMBIVIR® (trademark of GlaxoSmithKline (‘GSK’)) CONCERTA® (trademark of Alza Corporation (‘Alza’)) DAYTRANA® (trademark of Noven Pharmaceutical Inc. (‘Noven’)) DIPENTUM® (trademark of UCB Pharma Ltd (‘UCB’))
    [Show full text]
  • Stage New Drug Discovery
    Public Support for Late- Stage New Drug Discovery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Nayak, Rahul K. 2019. Public Support for Late-Stage New Drug Discovery. Doctoral dissertation, Harvard Medical School. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:41971479 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Scholarly Report submitted in partial fulfillment of the MD Degree at Harvard Medical School Date: 27 March 2019 Student Name: Rahul K Nayak, BSE Scholarly Report Title: Public support for late-stage new drug discovery Mentor Name(s) and Affiliations: Aaron S. Kesselheim, MD, JD, MPH, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA Collaborators, with Affiliations: Jerry Avorn, MD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 1 Abstract Title: Public support for late-stage new drug discovery Rahul K Nayak, Jerry Avorn, Aaron S. Kesselheim Purpose: To determine the role of publicly-supported research in the development of innovative new medications. Method: We examined patent data and drug discovery and development histories to assess the extent of public support for late-stage medication development for all new drugs approved by the US Food and Drug Administration (FDA) containing one or more new molecular entity approved between January 2008 and December 2017 via the new drug application pathway.
    [Show full text]
  • Annual Report on Form 20-F 2009
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ................... For the transition period from to Commission File Number: 001-31368 Sanofi-Aventis (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 174, avenue de France, 75013 Paris, France (Address of principal executive offices) Karen Linehan, Senior Vice President Legal Affairs and General Counsel 174, avenue de France, 75013 Paris, France. Fax: 011 + 33 1 53 77 43 03 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Name of each exchange Title of each class: on which registered: American Depositary Shares, each New York Stock Exchange representing one half of one ordinary share, par value €2 per share Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Securities registered pursuant to Section 12(g) of the Act: American Depositary Shares, each representing one quarter of a Participating Share Series A, par value €70.89 per share (removed from listing and registration on the New York Stock Exchange effective July 31, 1995).
    [Show full text]
  • FTSE 100 Historic Additions and Deletions
    FTSE 100 Historic Additions and Deletions ftserussell.com An LSEG Business September 2021 FTSE 100 – Historic Additions and Deletions Date Added Deleted Notes 19-Jan-84 Charterhouse J Rothschild Eagle Star Corporate Event - Acquisition of Eagle Star by BAT Industries 02-Apr-84 Lonrho Magnet & Southerns 02-Jul-84 Reuters Edinburgh Investment Trust 02-Jul-84 Woolworths Barratt Development 19-Jul-84 Enterprise Oil Bowater Corporation Corporate Event - Sub division of company into Bowater Inds and Bowater Inc 01-Oct-84 Willis Faber Wimpey (George) & Co 01-Oct-84 Granada Group Scottish & Newcastle Breweries 01-Oct-84 Dowty Group MFI Furniture Corporate Event - Acquisition of MFI Furniture by Associated Dairies Group 04-Dec-84 British Telecom Johnson Matthey Fast Entry 02-Jan-85 Dee Corporation Dowty Group 02-Jan-85 Argyll Group Berisford (S & W) 02-Jan-85 MFI Furniture RMC Group 02-Jan-85 Dixons Group Dalgety 01-Feb-85 Jaguar Hambro Life Corporate Event - Acquisition of Hambro Life by BAT Industries 01-Apr-85 Guinness (Arthur) & Son Enterprise Oil 01-Apr-85 Smith Industries House of Fraser Corporate Event - Acquisition of House of Fraser by Alfayed Investment Trust 01-Apr-85 Ranks Hovis McDougall MFI Furniture Corporate Event - Acquisition of MFI Furniture by Associated Dairies Group 01-Jul-85 Abbey Life Ranks Hovis McDougall 01-Jul-85 Debenhams Imperial Continental Gas Ass. 06-Aug-85 Bank of Scotland Debenhams 01-Oct-85 Habitat Mothercare Lonrho 02-Jan-86 Scottish & Newcastle Rothschild (J) Holdings 08-Jan-86 Storehouse Habitat Mothercare
    [Show full text]
  • Celltech Group Plc Annual Report and Accounts 2003
    Celltech Group plc Annual Report and Accounts 2003 Celltech is a leading European complementary capabilities through biotechnology company with a long-term collaborations with other pharma and commitment to the research and biotech companies.This strategy, development of innovative therapies for supported by its strong revenue stream, patients with serious diseases.Celltech is enables Celltech to maintain a substantial a recognised global leader in advanced investment in research and development antibody technologies, which together whilst maintaining its financial strength with its innovative small molecule and flexibility. capabilities, provide a strong platform for Corporate Statement development of first-in-class or best-in- The combination of these strengths class treatments for immune and underpins Celltech’s goal of becoming a inflammatory disorders and cancer. global biotechnology leader, which will be furthered by the successful Celltech is focused on maximising value development and commercialisation of its from its products by marketing its own key late-stage development product, products to specialist prescribers through CDP870, and by the rapid progression of its extensive US and European its promising early-stage pipeline commercial operations and by accessing products. 1 Chairman’s Statement 2 Chief Executive’s Statement 3 2003 Highlights 4 Development Portfolio Contents 6 Operational Review – Research and Development 14 Operational Review – Global Commercial 18 Financial Review 24 Board of Directors 26 Directors’ Report
    [Show full text]